司库奇尤单抗联合卡泊三醇软膏治疗中重度斑块状银屑病的效果和安全性  

Efficacy and Safety of Secukinumab Combined with Calcipotriol Ointment in the Treatment of Moderate to Severe Plaque Psoriasis

作　　者：孙叶建 孙秀文 毛建宇 SUN Yejian;SUN Xiuwen;MAO Jianyu(Huai’an Cancer Hospital,Huai’an 223200,China;不详)

机构地区：[1]淮安市肿瘤医院,江苏淮安223200

出　　处：《中外医学研究》2024年第34期26-30,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探究司库奇尤单抗联合卡泊三醇软膏治疗中重度斑块状银屑病的效果和安全性。方法:选取2022年2月—2023年12月淮安市肿瘤医院收治的126例中重度斑块状银屑病患者。根据随机数表法将其分为司库奇尤单抗组、卡泊三醇组和联合组,各42例。司库奇尤单抗组给予司库奇尤单抗治疗,卡泊三醇组给予卡泊三醇治疗,联合组给予司库奇尤单抗联合卡泊三醇治疗。比较三组治疗前及治疗12周后评分相关指标、免疫指标及炎症因子、代谢功能指标及不良反应。结果:治疗12周后,三组银屑病面积和严重程度指数(PASI)评分、银屑病体表面积严重程度评分(BSA)、皮肤病生活质量指数评分(DLQI)评分均降低,联合组PASI评分、BSA、DLQI评分均低于司库奇尤单抗组和卡泊三醇组,司库奇尤单抗组PASI评分、BSA、DLQI评分均低于卡泊三醇组,差异有统计学意义(P<0.05)。治疗12周后,三组CD4^(+)升高,CD8^(+)及白细胞介素-2(IL-2)、白细胞介素-17(IL-17)均降低,联合组CD4^(+)高于司库奇尤单抗组和卡泊三醇组,CD8^(+)及IL-2、IL-17水平均低于司库奇尤单抗组和卡泊三醇组,卡泊三醇组CD4^(+)低于司库奇尤单抗组,IL-2、IL-17水平均高于司库奇尤单抗组,差异有统计学意义(P<0.05)。治疗12周后,三组甘油三酯(TG)、总胆固醇(TC)、尿酸(UA)、谷丙转氨酶(ALT)、谷草转氨酶(AST)比较,差异无统计学意义(P>0.05)。三组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:司库奇尤单抗联合卡泊三醇软膏治疗中重度斑块状银屑病在疗效上较单独用药更为有效,且安全性良好。Objective:To explore the efficacy and safety of Secukinumab combined with Calcipotriol Ointment in the treatment of moderate to severe plaque psoriasis.Method:A total of 126 patients with moderate to severe plaque psoriasis admitted to Huai’an Cancer Hospital from February 2022 to December 2023 were selected.According to the random number table method,they were divided into Secukinumab group,Calcipotriol group,and Combination group,with 42 cases in each group.The Secukinumab group was treated with Secukinumab,the Calcipotriol group was treated with Calcipotriol,and the combination group was treated with Secukinumab combined with Calcipotriol.The score related indicators,immune indicators,inflammatory factors,metabolic function indicators before and after 12 weeks of treatment,and adverse reactions among three groups were compared.Result:After 12 weeks of treatment,the psoriasis area and severity index(PASI),silver chip disease body surface area severity score(BSA),and skin disease quality of life index score(DLQI)scores of the three groups all decreased,the PASI,BSA,and DLQI scores of the combination group were lower than those of the Secukinumab group and the Calcipotriol group,the PASI,BSA,and DLQI scores of the Secukinumab group were all lower than those of the Calcipotriol group,and the differences were statistically significant(P<0.05).After 12 weeks of treatment,CD4^(+)levels increased,while CD8^(+),interleukin-2(IL-2),and interleukin-17(IL-17)levels decreased in all three groups,the combination group had higher CD4^(+)levels and lower CD8^(+),IL-2,and IL-17 levels compared to the Secukinumab group and Calcipotriol group,the Calcipotriol group had lower CD4^(+)levels and higher IL-2 and IL-17 levels than the Secukinumab group,the differences were statistically significant(P<0.05).After 12 weeks of treatment,there was no statistically significant difference in triglycerides(TG),total cholesterol(TC),uric acid(UA),alanine aminotransferase(ALT),and aspartate aminotransferase(AST)among the three groups(P>0.05

关 键 词：斑块状银屑病 司库奇尤单抗 卡泊三醇 疗效 安全性 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]